Amolyt Pharma

Amolyt Pharma

Recherche en biotechnologie

Advancing peptides for the treatment of rare endocrine and related diseases

À propos

Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Secteur
Recherche en biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Ecully
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2015
Domaines
Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, Endocrine Disease et Rare Disease

Lieux

Employés chez Amolyt Pharma

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement